Last Updated on April 24, 2024 by Hitesh Goyal
Form 483
Cipla, the pharmaceutical giant, divulged that the United States Food and Drug Administration (USFDA) has issued Form 483, comprising six observations post-assessment of its Patalganga manufacturing unit in Maharashtra.
Rigorous Examination Conducted by USFDA
The United States Food and Drug Administration (USFDA) undertook a recent evaluation of current good manufacturing practices (cGMP) at Cipla’s Patalganga manufacturing site, spanning from March 28, 2024, to April 4, 2024.
Commitment to Compliance and Resolution
In its regulatory disclosure, Cipla conveyed that subsequent to the scrutiny’s conclusion, the organization garnered six scrutiny-based observations delineated in Form 483.
Assuring a proactive stance, the company pledged to collaborate closely with the USFDA and diligently address these concerns within the specified timeframe.
About Cipla
Renowned for its emphasis on dynamic and sustainable expansion, intricate generics, and augmentation of its product spectrum across diverse markets, Cipla stands as a global frontrunner in the pharmaceutical domain.
Its operational ambit encompasses India, South Africa, North America, along with pivotal regulated and burgeoning markets worldwide.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA grants VAI classification to Granules India
USFDA issued Form 483 with 4 observations to Alembic Pharma
USFDA issues EIR to Torrent Pharma for Gujarat Plant
Aurobindo Pharma’s Arm gets 7 observations from USFDA
USFDA’s Agenda for Indian Pharma Industry
Telangana Drug Inspectors Now Eligible to Observe USFDA Inspections
USFDA grants VAI classification to Granules India
DTAB: Study required to substitute the Prescriptions at Jan Aushadhi Stores
DCC: All states to provide data on Vaccine
Price Modifications Announcement by the NPPA
Altered Provisions: Jan Vishwas (Provisions Amendment) Act, 2023
USFDA approval granted for Migalastat Capsules
DCC to set deadline for adding details on Sugam portal
Understanding the CDSCO’s Decision on Clinical Trial Waiver
Understanding the Deliberations on 16 FDCs by the DTAB Subcommittee
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
